4/A: Eyenovia Director Corrects Filing on Beneficial Ownership After Proposed Merger with Betaliq

Tsontcho Ianchulev, a director at Eyenovia, files an amended Form 4 to correct a clerical error regarding the amount of securities beneficially owned directly, following a reverse stock split and ahead of a proposed business combination with Betaliq, Inc.

Summary

• Tsontcho Ianchulev, a director of Eyenovia, Inc., filed an amended Form 4 (Form 4/A) with the SEC to correct a clerical error in a previous filing.
• The error concerned the amount of securities beneficially owned directly by Ianchulev.
• The original filing was made on April 23, 2025, and the amended filing is dated April 29, 2025.
• The corrected filing reports that Ianchulev directly owns 10,122 shares of Eyenovia common stock.
• Ianchulev also indirectly owns 7,583 shares through Private Medical Equity, Inc. and 75 shares through The Meliora Trust, but disclaims beneficial ownership except to the extent of his pecuniary interest.
• 5,000 restricted stock units were acquired that will fully vest upon the closing of the Issuer's proposed business combination with Betaliq, Inc.
• Vesting is subject to the Reporting Person's continued service to the Issuer.
• On January 31, 2025, Eyenovia effected a 1-for-80 reverse stock split, which has been reflected in the reported ownership numbers.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't contain information that would significantly impact investor sentiment positively or negatively. The mention of the proposed merger with Betaliq is a slightly positive sign, but the filing itself is neutral.

Future Outlook

The document mentions a proposed business combination with Betaliq, Inc., which will trigger the vesting of restricted stock units if the deal closes and the Reporting Person continues to serve the Issuer.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, such as directors and officers. This filing is related to a proposed merger, which is a common event in the pharmaceutical industry as companies seek to expand their product pipelines and market reach.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders regarding insider ownership.
• The proposed merger with Betaliq, Inc. could impact shareholders, employees, and other stakeholders depending on the terms and outcome of the transaction.

Next Steps

• The proposed business combination with Betaliq, Inc. is pending.

Key Dates

Keywords

Eyenovia, Tsontcho Ianchulev, SEC Form 4, Beneficial Ownership, Amendment, Reverse Stock Split, Betaliq, Merger